↓ Skip to main content

The role of phosphodiesterase-5 inhibitors in prostatic inflammation: a review

Overview of attention for article published in Journal of Inflammation, September 2015
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Above-average Attention Score compared to outputs of the same age and source (62nd percentile)

Mentioned by

twitter
3 X users

Citations

dimensions_citation
34 Dimensions

Readers on

mendeley
53 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
The role of phosphodiesterase-5 inhibitors in prostatic inflammation: a review
Published in
Journal of Inflammation, September 2015
DOI 10.1186/s12950-015-0099-7
Pubmed ID
Authors

Christina Alves Peixoto, Fabiana Oliveira dos Santos Gomes

Abstract

Clinical and basic experimental evidence indicates that chronic inflammation is the greatest factor in benign prostatic hyperplasia (BPH) progression, which is the most common cause of Lower Urinary Tract Symptoms (LUTS). The use of anti-inflammatory agents such as steroids, cyclooxygenase-2 (COX-2) and phytotherapics have been investigated as forms of treatment for various prostate diseases. Recent evidence has demonstrated that PDE5 inhibitors (PDE5Is) improve symptoms of BPH/LUTS, possibly as a result of the relaxing of the smooth muscle fibers of the bladder and prostate by NO/cGMPc signaling, or by improving RhoA/Rho-kinase (ROCK), and reduction of the hyperactivity of the autonomic nervous system. However, some results have suggested that besides vasodilatation and their anti-proliferative effect, PDE5Is exert a direct anti-inflammatory effect, by raising cGMP. Given that inflammation is major factor in benign prostatic hyperplasia (BPH) progression, PDE5Is could act also restore prostatic function as they act as potent anti-inflammatory drugs. This review aims to provide a comprehensive summary of the use of phosphodiesterase-5 inhibitors to treat prostatic inflammation.

X Demographics

X Demographics

The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 53 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 53 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 9 17%
Student > Master 7 13%
Student > Doctoral Student 5 9%
Student > Bachelor 5 9%
Student > Ph. D. Student 4 8%
Other 7 13%
Unknown 16 30%
Readers by discipline Count As %
Medicine and Dentistry 14 26%
Agricultural and Biological Sciences 8 15%
Pharmacology, Toxicology and Pharmaceutical Science 5 9%
Biochemistry, Genetics and Molecular Biology 2 4%
Chemistry 2 4%
Other 5 9%
Unknown 17 32%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 February 2022.
All research outputs
#15,170,530
of 25,374,917 outputs
Outputs from Journal of Inflammation
#159
of 425 outputs
Outputs of similar age
#137,190
of 281,198 outputs
Outputs of similar age from Journal of Inflammation
#3
of 8 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. This one is in the 38th percentile – i.e., 38% of other outputs scored the same or lower than it.
So far Altmetric has tracked 425 research outputs from this source. They receive a mean Attention Score of 4.9. This one has gotten more attention than average, scoring higher than 61% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 281,198 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 49th percentile – i.e., 49% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 8 others from the same source and published within six weeks on either side of this one. This one has scored higher than 5 of them.